Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck
In the last minute, late-stage race to the market with a new round of psoriasis drugs, India’s Sun Pharmaceuticals is making its own bid with a new drug called tildrakizumab. In-licensed from Merck, which agreed to handle the late-stage work for Sun for the former MK-3222, it’s another IL-23 drug, like J&J’s guselkumab.
But it didn’t perform as well as the J&J drug in late-stage development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.